Ronni Thermann Reitz Plovsing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ronni Thermann Reitz Plovsing has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Andreas Ronit
Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre Hospitals, Hvidovre, Denmark
3 shared publications- Bodil Steen Rasmussen
Department of Anaesthesia and Intensive Care Aalborg University Hospital Aalborg Denmark
3 shared publications - Anders Granholm
Department of Intensive Care Copenhagen University Hospital–Rigshospitalet Copenhagen Denmark
2 shared publications Anders Perner
Department of Intensive Care Copenhagen University Hospital—Rigshospitalet Copenhagen Denmark
2 shared publications- Maj‐Brit Nørregaard Kjær
Department of Intensive Care Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark
2 shared publications Margit Smitt
Department of Anaesthesiology and Intensive Care Glostrup Hospital Copenhagen Denmark
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (10) , e70342
Electronic Patient‐Reported Health‐Related Quality of Life Trajectories in ICU Survivors: A Multicentre Pilot Study‐Within‐a‐Trial Protocol
Background: Patient‐important outcomes beyond mortality, particularly health‐related quality of life (HRQoL), are frequently used in intensive care unit (ICU) trials. However, HRQoL assessment remains challenging due to methodological complexities, including poorly defined recovery trajectories, lack of consensus on measurement instruments, complexity of statistical analysis, and missing data. Electronic patient‐reported outcomes (ePROs) may improve data collection and efficiency, though their feasibility in ICU survivors is uncertain. Methods: This protocol outlines a longitudinal, multicentre pilot study‐within‐a‐trial aimed at evaluating the feasibility of ePRO‐based HRQoL follow‐up and exploring a trajectory‐based approach to HRQoL characterisation after critical illness. We plan to enrol 100 participants already undergoing 180‐day HRQoL follow‐up in the Intensive Care Platform Trial (INCEPT) to complete monthly EQ‐5D‐5L surveys delivered by text messages from 6 to 12 months after randomisation. Feasibility outcomes include enrolment and response rate, time to completion, reminder‐dependency, attrition pattern, agreement between modes of collection, and accessibility. Agreement between telephone‐ and ePRO‐based assessments at 180 days will be evaluated at the group and at the individual level. Longitudinal EQ‐5D‐5L index values and visual analogue scale trajectories will be analysed using area‐under‐the‐curve methods based on linear interpolation. Scenario‐based sensitivity analyses will assess the potential impact of unobserved mortality among dropouts. Discussion: We hypothesise that ePRO‐based repeated assessments of HRQoL will support the goal of optimised data collection methods, while ensuring resources control. Moreover, identification of a candidate approach to HRQoL characterisation may shed light into the full recovery trajectory of ICU survivors and improve the interpretation and clinical relevance of HRQoL outcome assessments.
- 29 September 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (10) , e70342
Open AccessElectronic Patient‐Reported Health‐Related Quality of Life Trajectories in ICU Survivors: A Multicentre Pilot Study‐Within‐a‐Trial Protocol
Background: Patient‐important outcomes beyond mortality, particularly health‐related quality of life (HRQoL), are frequently used in intensive care unit (ICU) trials. However, HRQoL assessment remains challenging due to methodological complexities, including poorly defined recovery trajectories, lack of consensus on measurement instruments, complexity of statistical analysis, and missing data. Electronic patient‐reported outcomes (ePROs) may improve data collection and efficiency, though their feasibility in ICU survivors is uncertain. Methods: This protocol outlines a longitudinal, multicentre pilot study‐within‐a‐trial aimed at evaluating the feasibility of ePRO‐based HRQoL follow‐up and exploring a trajectory‐based approach to HRQoL characterisation after critical illness. We plan to enrol 100 participants already undergoing 180‐day HRQoL follow‐up in the Intensive Care Platform Trial (INCEPT) to complete monthly EQ‐5D‐5L surveys delivered by text messages from 6 to 12 months after randomisation. Feasibility outcomes include enrolment and response rate, time to completion, reminder‐dependency, attrition pattern, agreement between modes of collection, and accessibility. Agreement between telephone‐ and ePRO‐based assessments at 180 days will be evaluated at the group and at the individual level. Longitudinal EQ‐5D‐5L index values and visual analogue scale trajectories will be analysed using area‐under‐the‐curve methods based on linear interpolation. Scenario‐based sensitivity analyses will assess the potential impact of unobserved mortality among dropouts. Discussion: We hypothesise that ePRO‐based repeated assessments of HRQoL will support the goal of optimised data collection methods, while ensuring resources control. Moreover, identification of a candidate approach to HRQoL characterisation may shed light into the full recovery trajectory of ICU survivors and improve the interpretation and clinical relevance of HRQoL outcome assessments.
- Open Access
- 31 August 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (9) , e70324
Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial
Background: Meropenem and piperacillin/tazobactam are commonly used empirical antibiotics in critically ill adults with sepsis, but whether one is superior to the other is uncertain. Methods: The Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial is an ongoing investigator‐initiated, randomised, open‐label, adaptive clinical trial with an integrated feasibility phase comparing empirical treatment with meropenem versus piperacillin/tazobactam in critically ill adults with sepsis. The integrated feasibility phase enrolled 200 participants across 10 intensive care units (ICUs) in Denmark between 28 June and 12 December 2025. Five pre‐specified feasibility criteria were evaluated; if all feasibility criteria were met, the trial would proceed unaltered, whereas failure to meet one or more criteria would require intervention and re‐evaluation. Results: We randomised 200 of 284 screened patients (70.4%). The median age was 70 years (interquartile range (IQR): 60–77), 65.5% were males. At randomisation, 80.0% received vasopressors or inotropes, and 43.5% were on invasive mechanical ventilation. Four of five pre‐specified feasibility criteria were met: time to completion of the feasibility phase (5.5 months vs. threshold < 12.0 months), recruitment proportion (70.4% vs. threshold ≥ 50.0%), proportion of participants without consent to the continued collection of data (2.5% vs. threshold < 5.0%) and protocol adherence (81.0% vs. threshold ≥ 75.0%). The proportion of participants with timely primary outcome data availability (30‐day mortality) within 45 days was 85.5% and below the pre‐specified threshold of ≥ 95.0%. The proportions were low in the first 3 months (33.3%, 22.2% and 30.8%, respectively), increasing to 95.8% in the last month of the feasibility phase. All‐cause mortality at 30 days was 30.5%, and specific serious adverse reactions occurred in 4.0% of participants. Conclusions: In this integrated feasibility evaluation of the EMPRESS trial comparing empirical meropenem versus piperacillin/tazobactam in critically ill adults with sepsis, four of five pre‐specified feasibility criteria were met. The unmet criterion, timely primary outcome data availability, improved substantially during the feasibility phase. We consider the trial feasible and will proceed without modifications. Editorial Comment: This feasibility study assessed recruitment, randomised allocation and data collection for the multicentre EMPRESS trial. For adaptive trials on trial platforms, careful interim checking of trial design functions is an important and necessary process. Trial Registration: Clinical Trials Information System EUCT number: 2023‐509703‐33‐00; ClinicalTrials.gov identifier: NCT06184659; Universal Trial Number: U1111‐1301‐6379
- 31 August 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (9) , e70324
Open AccessEmpirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial
Background: Meropenem and piperacillin/tazobactam are commonly used empirical antibiotics in critically ill adults with sepsis, but whether one is superior to the other is uncertain. Methods: The Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial is an ongoing investigator‐initiated, randomised, open‐label, adaptive clinical trial with an integrated feasibility phase comparing empirical treatment with meropenem versus piperacillin/tazobactam in critically ill adults with sepsis. The integrated feasibility phase enrolled 200 participants across 10 intensive care units (ICUs) in Denmark between 28 June and 12 December 2025. Five pre‐specified feasibility criteria were evaluated; if all feasibility criteria were met, the trial would proceed unaltered, whereas failure to meet one or more criteria would require intervention and re‐evaluation. Results: We randomised 200 of 284 screened patients (70.4%). The median age was 70 years (interquartile range (IQR): 60–77), 65.5% were males. At randomisation, 80.0% received vasopressors or inotropes, and 43.5% were on invasive mechanical ventilation. Four of five pre‐specified feasibility criteria were met: time to completion of the feasibility phase (5.5 months vs. threshold < 12.0 months), recruitment proportion (70.4% vs. threshold ≥ 50.0%), proportion of participants without consent to the continued collection of data (2.5% vs. threshold < 5.0%) and protocol adherence (81.0% vs. threshold ≥ 75.0%). The proportion of participants with timely primary outcome data availability (30‐day mortality) within 45 days was 85.5% and below the pre‐specified threshold of ≥ 95.0%. The proportions were low in the first 3 months (33.3%, 22.2% and 30.8%, respectively), increasing to 95.8% in the last month of the feasibility phase. All‐cause mortality at 30 days was 30.5%, and specific serious adverse reactions occurred in 4.0% of participants. Conclusions: In this integrated feasibility evaluation of the EMPRESS trial comparing empirical meropenem versus piperacillin/tazobactam in critically ill adults with sepsis, four of five pre‐specified feasibility criteria were met. The unmet criterion, timely primary outcome data availability, improved substantially during the feasibility phase. We consider the trial feasible and will proceed without modifications. Editorial Comment: This feasibility study assessed recruitment, randomised allocation and data collection for the multicentre EMPRESS trial. For adaptive trials on trial platforms, careful interim checking of trial design functions is an important and necessary process. Trial Registration: Clinical Trials Information System EUCT number: 2023‐509703‐33‐00; ClinicalTrials.gov identifier: NCT06184659; Universal Trial Number: U1111‐1301‐6379
- Open Access
- 26 February 2025
- Published by Wiley in Experimental Physiology
- Vol. 111 (9) , 3870-3873
Blistering barnacles: Space physiology in The Adventures of Tintin
- 26 February 2025
- Published by Wiley in Experimental Physiology
- Vol. 111 (9) , 3870-3873
Open AccessBlistering barnacles: Space physiology in The Adventures of Tintin
- Open Access
- 12 April 2024
- Published by Wiley in Experimental Physiology
- Vol. 109 (6) , 837-838
The mouse to man conundrum: Revisiting an old lung injury model to study repurposed drugs for COVID‐19 treatment
- 12 April 2024
- Published by Wiley in Experimental Physiology
- Vol. 109 (6) , 837-838
Open AccessThe mouse to man conundrum: Revisiting an old lung injury model to study repurposed drugs for COVID‐19 treatment
- Open Access
- 20 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1353012
Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS
Background: Type I interferon (IFN-I) and IFN autoantibodies play a crucial role in controlling SARS-CoV-2 infection. The levels of these mediators have only rarely been studied in the alveolar compartment in patients with COVID-19 acute respiratory distress syndrome (CARDS) but have not been compared across different ARDS etiologies, and the potential effect of dexamethasone (DXM) on these mediators is not known.Methods: We assessed the integrity of the alveolo-capillary membrane, interleukins, type I, II, and III IFNs, and IFN autoantibodies by studying the epithelial lining fluid (ELF) volumes, alveolar concentration of protein, and ELF-corrected concentrations of cytokines in two patient subgroups and controls.Results: A total of 16 patients with CARDS (four without and 12 with DXM treatment), eight with non-CARDS, and 15 healthy controls were included. The highest ELF volumes and protein levels were observed in CARDS. Systemic and ELF-corrected alveolar concentrations of interleukin (IL)-6 appeared to be particularly low in patients with CARDS receiving DXM, whereas alveolar levels of IL-8 were high regardless of DXM treatment. Alveolar levels of IFNs were similar between CARDS and non-CARDS patients, and IFNα and IFNω autoantibody levels were higher in patients with CARDS and non-CARDS than in healthy controls.Conclusions: Patients with CARDS exhibited greater alveolo-capillary barrier disruption with compartmentalization of IL-8, regardless of DXM treatment, whereas systemic and alveolar levels of IL-6 were lower in the DXM-treated subgroup. IFN-I autoantibodies were higher in the BALF of CARDS patients, independent of DXM, whereas IFN autoantibodies in plasma were similar to those in controls.
- 20 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1353012
Open AccessAlveolar cytokines and interferon autoantibodies in COVID-19 ARDS
Background: Type I interferon (IFN-I) and IFN autoantibodies play a crucial role in controlling SARS-CoV-2 infection. The levels of these mediators have only rarely been studied in the alveolar compartment in patients with COVID-19 acute respiratory distress syndrome (CARDS) but have not been compared across different ARDS etiologies, and the potential effect of dexamethasone (DXM) on these mediators is not known.Methods: We assessed the integrity of the alveolo-capillary membrane, interleukins, type I, II, and III IFNs, and IFN autoantibodies by studying the epithelial lining fluid (ELF) volumes, alveolar concentration of protein, and ELF-corrected concentrations of cytokines in two patient subgroups and controls.Results: A total of 16 patients with CARDS (four without and 12 with DXM treatment), eight with non-CARDS, and 15 healthy controls were included. The highest ELF volumes and protein levels were observed in CARDS. Systemic and ELF-corrected alveolar concentrations of interleukin (IL)-6 appeared to be particularly low in patients with CARDS receiving DXM, whereas alveolar levels of IL-8 were high regardless of DXM treatment. Alveolar levels of IFNs were similar between CARDS and non-CARDS patients, and IFNα and IFNω autoantibody levels were higher in patients with CARDS and non-CARDS than in healthy controls.Conclusions: Patients with CARDS exhibited greater alveolo-capillary barrier disruption with compartmentalization of IL-8, regardless of DXM treatment, whereas systemic and alveolar levels of IL-6 were lower in the DXM-treated subgroup. IFN-I autoantibodies were higher in the BALF of CARDS patients, independent of DXM, whereas IFN autoantibodies in plasma were similar to those in controls.
- Open Access
- 8 June 2023
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 67 (9) , 1239-1248
Long‐term outcomes in COVID‐19 patients admitted to intensive care in Denmark: A nationwide observational study
Background: Among ICU patients with COVID‐19, it is largely unknown how the overall outcome and resource use have changed with time, different genetic variants, and vaccination status.Methods: For all Danish ICU patients with COVID‐19 from March 10, 2020 to March 31, 2022, we manually retrieved data on demographics, comorbidities, vaccination status, use of life support, length of stay, and vital status from medical records. We compared patients based on the period of admittance and vaccination status and described changes in epidemiology related to the Omicron variant.Results: Among all 2167 ICU patients with COVID‐19, 327 were admitted during the first (March 10–19, 2020), 1053 during the second (May 20, 2020 to June 30, 2021) and 787 during the third wave (July 1, 2021 to March 31, 2022). We observed changes over the three waves in age (median 72 vs. 68 vs. 65 years), use of invasive mechanical ventilation (81% vs. 58% vs. 51%), renal replacement therapy (26% vs. 13% vs. 12%), extracorporeal membrane oxygenation (7% vs. 3% vs. 2%), duration of invasive mechanical ventilation (median 13 vs. 13 vs. 9 days) and ICU length of stay (median 13 vs. 10 vs. 7 days). Despite these changes, 90‐day mortality remained constant (36% vs. 35% vs. 33%). Vaccination rates among ICU patients were 42% as compared to 80% in society. Unvaccinated versus vaccinated patients were younger (median 57 vs. 73 years), had less comorbidity (50% vs. 78%), and had lower 90‐day mortality (29% vs. 51%). Patient characteristics changed significantly after the Omicron variant became dominant including a decrease in the use of COVID‐specific pharmacological agents from 95% to 69%.Conclusions: In Danish ICUs, the use of life support declined, while mortality seemed unchanged throughout the three waves of COVID‐19. Vaccination rates were lower among ICU patients than in society, but the selected group of vaccinated patients admitted to the ICU still had very severe disease courses. When the Omicron variant became dominant a lower fraction of SARS‐CoV‐2 positive patients received COVID treatment indicating other causes for ICU admission.
- 8 June 2023
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 67 (9) , 1239-1248
Open AccessLong‐term outcomes in COVID‐19 patients admitted to intensive care in Denmark: A nationwide observational study
Background: Among ICU patients with COVID‐19, it is largely unknown how the overall outcome and resource use have changed with time, different genetic variants, and vaccination status.Methods: For all Danish ICU patients with COVID‐19 from March 10, 2020 to March 31, 2022, we manually retrieved data on demographics, comorbidities, vaccination status, use of life support, length of stay, and vital status from medical records. We compared patients based on the period of admittance and vaccination status and described changes in epidemiology related to the Omicron variant.Results: Among all 2167 ICU patients with COVID‐19, 327 were admitted during the first (March 10–19, 2020), 1053 during the second (May 20, 2020 to June 30, 2021) and 787 during the third wave (July 1, 2021 to March 31, 2022). We observed changes over the three waves in age (median 72 vs. 68 vs. 65 years), use of invasive mechanical ventilation (81% vs. 58% vs. 51%), renal replacement therapy (26% vs. 13% vs. 12%), extracorporeal membrane oxygenation (7% vs. 3% vs. 2%), duration of invasive mechanical ventilation (median 13 vs. 13 vs. 9 days) and ICU length of stay (median 13 vs. 10 vs. 7 days). Despite these changes, 90‐day mortality remained constant (36% vs. 35% vs. 33%). Vaccination rates among ICU patients were 42% as compared to 80% in society. Unvaccinated versus vaccinated patients were younger (median 57 vs. 73 years), had less comorbidity (50% vs. 78%), and had lower 90‐day mortality (29% vs. 51%). Patient characteristics changed significantly after the Omicron variant became dominant including a decrease in the use of COVID‐specific pharmacological agents from 95% to 69%.Conclusions: In Danish ICUs, the use of life support declined, while mortality seemed unchanged throughout the three waves of COVID‐19. Vaccination rates were lower among ICU patients than in society, but the selected group of vaccinated patients admitted to the ICU still had very severe disease courses. When the Omicron variant became dominant a lower fraction of SARS‐CoV‐2 positive patients received COVID treatment indicating other causes for ICU admission.
- 23 March 2023
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 67 (6) , 779-787
PaCO2 trajectories in mechanically ventilated patients with COVID‐19: A population‐based cohort study
Objective: To identify PaCO2 trajectories and assess their associations with mortality in critically ill patients with coronavirus disease 2019 (COVID-19) during the first and second waves of the pandemic in Denmark. Design: A population-based cohort study with retrospective data collection.Patients: All COVID-19 patients were treated in eight intensive care units (ICUs) in the Capital Region of Copenhagen, Denmark, between March 1, 2020 and March 31, 2021. Measurements: Data from the electronic health records were extracted, and latent class analyses were computed based on up to the first 3 weeks of mechanical ventilation to depict trajectories of PaCO2 levels. Multivariable Cox regression analyses were used to calculate adjusted hazard ratios (aHRs) for Simplified Acute Physiology Score 3, sex and age with 95% confidence intervals (CIs) for death according to PaCO2 trajectories. Main results: In latent class trajectory models, including 25,318 PaCO2 measurements from 244 patients, three PaCO2 latent class trajectories were identified: a low isocapnic (Class I; n = 130), a high isocapnic (Class II; n = 80), as well as a progressively hypercapnic (Class III; n = 34) trajectory. Mortality was higher in Class II [aHR: 2.16 {1.26-3.68}] and Class III [aHR: 2.97 {1.63-5.40}]) compared to Class I (reference). Conclusion: Latent class analysis of arterial blood gases in mechanically ventilated COVID-19 patients identified distinct PaCO2 trajectories, which were independently associated with mortality.
- 23 March 2023
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 67 (6) , 779-787
PaCO2 trajectories in mechanically ventilated patients with COVID‐19: A population‐based cohort study
Objective: To identify PaCO2 trajectories and assess their associations with mortality in critically ill patients with coronavirus disease 2019 (COVID-19) during the first and second waves of the pandemic in Denmark. Design: A population-based cohort study with retrospective data collection.Patients: All COVID-19 patients were treated in eight intensive care units (ICUs) in the Capital Region of Copenhagen, Denmark, between March 1, 2020 and March 31, 2021. Measurements: Data from the electronic health records were extracted, and latent class analyses were computed based on up to the first 3 weeks of mechanical ventilation to depict trajectories of PaCO2 levels. Multivariable Cox regression analyses were used to calculate adjusted hazard ratios (aHRs) for Simplified Acute Physiology Score 3, sex and age with 95% confidence intervals (CIs) for death according to PaCO2 trajectories. Main results: In latent class trajectory models, including 25,318 PaCO2 measurements from 244 patients, three PaCO2 latent class trajectories were identified: a low isocapnic (Class I; n = 130), a high isocapnic (Class II; n = 80), as well as a progressively hypercapnic (Class III; n = 34) trajectory. Mortality was higher in Class II [aHR: 2.16 {1.26-3.68}] and Class III [aHR: 2.97 {1.63-5.40}]) compared to Class I (reference). Conclusion: Latent class analysis of arterial blood gases in mechanically ventilated COVID-19 patients identified distinct PaCO2 trajectories, which were independently associated with mortality.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (1) , 81-91
Compartmental immunophenotyping in COVID-19 ARDS: A case series
- 1 January 2021
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (1) , 81-91
Open AccessCompartmental immunophenotyping in COVID-19 ARDS: A case series